Bibliografia
1. Amstrong PJ, Blanchard G. Hepatic lipidosis. Vet. Clin. North Am. Small Pract. 2009;39(3):599-616.
2. Brenner K, KuKanisch KS, Smee NM. Refeeding syndrome in a cat with hepatic lipidosis. J. Feline Med. Surg. 2011;13:614-617.
3. Crook MA. Refeeding syndrome: problems with definition and management. Nutrition. 2014;30(11-12):1448-1455.
4. DeAvilla MD, Leech EB. Hypoglycemia associated with refeeding syndrome in a cat. J. Vet. Emerg. Crit. Care. 2016;26(6):798-803.
5. Fitzpatrick RL, Quimby JM, Benson KK et coll. In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. J. Vet. Intern. Med. 2018;32(6):1951-1957.
6. Justin RB, Hohenhaus AE. Hypophosphatemia associated with enteral alimentation in cats. J. Vet. Intern. Med. 1995;4:228-233.
7. Kuzi S, Segev G, Kedar S et coll. Prognostic markers in feline hepatic lipidosis: a retrospective study of 71 cats. Vet. Rec. 2017;181(19):512.
8. Khoo AWS, Taylor SM, Owens TJ. Successful management and recovery following severe prolonged starvation in a dog. J. Vet. Emerg. Crit. Care. 2019;29(5):542-548.
9. Plumb DC. Plumb’s Veterinary Drug Handbook, 7th edition, Wiley Blackwell. 2011:1299p.
TORNA INDIETROPatologia ed epidemiologia della vasculopatia glomerulare cutanea e renale
La vasculopatia glomerulare cutanea e renale (CRGV) è stata riconosciuta come una condizione che mette potenzialmente a rischio la vita dei cani nel Regno Unito dal 2012, sebbene vi sia stato un singolo caso (non azotemico) segnalato nel Regno Unito nel 2000.
